The Memo: Nami Surgical Unlocking the Future of Ultrasonic Surgery

Under the direction of CEO Nikki Palfrey and Co-Founder and COO Nico Fenu, PhD, Nami Surgical is developing a meaningful new capability in robotic-assisted surgery: integrated ultrasonic advanced energy with wristed articulation. Built on deep expertise in ultrasonics and designed specifically for robotic integration, the company is working to address a functional gap that has persisted as surgical robotics has scaled, creating a platform intended to bring the speed, precision, and safety advantages of ultrasonic energy into a new generation of procedures.

Origin Story

Nami Surgical was founded in December 2021 by Dr. Nico Fenu and Dr. Rebecca Cleary, both alumni of the University of Glasgow’s Centre for Medical and Industrial Ultrasonics, the world’s largest academic ultrasonic engineering unit. The company emerged directly from Fenu’s PhD research, as well as the founders’ work within the Ultrasurge: Surgery Enabled by Ultrasonics program, giving Nami a foundation rooted in specialized scientific research and firsthand technical expertise.

Fenu completed his PhD focused on piezoelectric materials for ultrasonic surgery, while Cleary, now the company’s CTO, researched ultrasonic needles for bone penetration and received the prestigious R.W.B. Stephens Prize at the International Congress of Ultrasonics. Together, they identified a clear technology gap in the operating room: ultrasonic surgical tools had become indispensable in minimally invasive surgery, but their architecture had not evolved to match the demands of robotic platforms.

“As founders, Rebecca and I are deeply committed to improving patient outcomes. We are excited about the opportunities ahead in a rapidly growing global market,” said Fenu.

In December 2024, the company entered a new phase when Nikki Palfrey stepped into the CEO role after joining Nami’s board the previous year. With more than 25 years of medtech leadership experience spanning growth, global expansion, and M&A, Palfrey’s appointment marked Nami’s transition from advanced development toward market entry.

“Nami is exceptionally well-positioned to become a leading force in the robotic-assisted surgery market. I am excited to lead the company as we enter a new chapter focused on innovation, scale, and long-term value creation,” said Palfrey.

The Current Landscape

Advanced energy remains one of the highest-utilization consumable categories in minimally invasive surgery, and ultrasonic devices have become indispensable in many procedures. By simultaneously cutting and coagulating tissue, reducing thermal spread, improving hemostasis, and eliminating the need for instrument exchanges, these tools can contribute to faster, safer procedures.

The ultrasonic scalpel market is valued at approximately $2.7 billion globally, growing at an 8–10% CAGR, underpinned by 15–25 million procedures annually, according to the Nami team.

At the same time, surgical robotics is expected to exceed $25 billion by 2030, with over six million procedures projected.

Yet one important limitation remains. Robotic surgery is built around wristed precision, but ultrasonic energy instruments have not evolved in parallel. While many robotic tools articulate at the tip, current robotic ultrasonic energy devices remain constrained by architectures originally designed for handheld laparoscopic use.

Conventional ultrasonic systems rely on rigid waveguides to transfer energy into the surgical site. That architecture creates meaningful limitations in robotic environments, where maneuverability and articulation are central to the value proposition.

This leaves one of robotic surgery’s clearest functional gaps still unresolved, and one with meaningful strategic implications. Advanced energy represents a major recurring consumables category, and integrated ultrasonic capability could become an important differentiator as more robotic platforms compete for adoption.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-memo-nami-surgical-unlocking-the-future-of-ultrasonic-surgery 

Comments

Post a Comment

Popular posts from this blog

Cover Story: A Page from Ray Cohen’s Playbook: Scaling, Exiting, and Winning in Medtech

With four decades of company-building, IPOs, boardroom leadership, and monumental exits behind him, Raymond W. Cohen has become one of medtech’s most successful operators. But behind the financial wins — including the recent back-to-back $3.7 billion Axonics and $600 million SoniVie acquisitions by Boston Scientific — is a deeper story of Cohen’s contrarian, full-transparency, people-centered, no-BS approach to leadership and strategy. “People crave inspired, authentic, and transparent leadership that thinks big and acts boldly. They want to be enrolled in a vision of what is possible, and be recognized and compensated for creating measurable results, not be fed a bunch of platitudes.” A quote that is classic  Ray Cohen  — blunt, unapologetic, no-nonsense, and grounded in hard-won experience. With more than four decades in medtech, Cohen has done what many aspire to — build, lead, scale, and sell high-stakes, successful ventures with precision and zero fluff. Known for his no-...
Read more

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Microbot Medical and the Endovascular Robotics Opportunity Taking Shape

In November, Microbot Medical reached a meaningful milestone in the evolution of endovascular robotics, announcing that Emory University Hospital in Atlanta has become the first hospital worldwide to use the company’s LIBERTY system for patient care. Microbot is currently operating under a limited commercial release following FDA clearance, with a broader market launch planned for April 2026 at the Society of Interventional Radiology conference. While still early, the move signals growing confidence that robotic assistance inside the vasculature is beginning to transition from concept to clinical reality. To understand why this matters, it helps to step back and examine the numbers behind the endovascular robotics market and how Microbot’s approach fits into a rapidly evolving competitive landscape. Defining the Endovascular Procedure Landscape Endovascular procedures encompass any intervention performed from within a blood vessel. In practical terms, this includes coronary, periphe...
Read more